Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ALX148 is a fusion, consisting of the Fc region of immunoglobulin fused to the CD47 SIRPa-binding domain, that blocks the ability of CD47 to bind SIRPa on macrophages thereby promoting phagocytosis of tumor cells (PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
|DrugClasses||CD47 Antibody 13 Immune Checkpoint Inhibitor 95|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ALX148 + Atezolizumab||ALX148 Atezolizumab||0||1|
|ALX148 + Trastuzumab||ALX148 Trastuzumab||0||1|